Milestone Gene Therapies for Sickle Cell Disease Greenlit by FDA
(MedPage Today) -- The FDA approved two cell-based gene therapies, exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel (Lyfgenia), for sickle cell disease (SCD), the agency announced.
Marking the first FDA-approved therapy utilizing...
Source: MedPage Today Public Health - Category: American Health Source Type: news
More News: American Health | Gene Therapy | Genetics | International Medicine & Public Health | Sickle Cell Anemia